Literature DB >> 25995435

Multidisciplinary management of pancreatic cancer.

Margaret A Tempero1.   

Abstract

Pancreatic cancer remains a vexing treatment challenge, with a cure rate that remains just 7%. Two effective regimens--gemcitabine/nab-paclitaxel and FOLFIRINOX--have improved outcomes and are being used earlier in the disease. However, meaningful differences in outcomes may not be realized without novel strategies. Targeting of the immune system is an active area of research.
Copyright © 2015 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25995435     DOI： 10.6004/jnccn.2015.0208

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  6 in total

1.  Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity.

Authors:  David E Durrant; Anindita Das; Samya Dyer; Seyedmehrad Tavallai; Paul Dent; Rakesh C Kukreja
Journal:  Mol Pharmacol       Date:  2015-06-22       Impact factor: 4.436

Review 2.  Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).

Authors:  M Uccello; M Moschetta; G Mak; T Alam; C Murias Henriquez; H-T Arkenau
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

3.  Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response.

Authors:  Paola Cappello; Elisabetta Tonoli; Roberta Curto; Daniele Giordano; Mirella Giovarelli; Francesco Novelli
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

Review 4.  Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.

Authors:  Han-Xiang Zhan; Jian-Wei Xu; Dong Wu; Zhi-Yang Wu; Lei Wang; San-Yuan Hu; Guang-Yong Zhang
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

5.  LncRNA IGBP1-AS1/miR-24-1/ZIC3 loop regulates the proliferation and invasion ability in breast cancer.

Authors:  Deqin Chen; Yangfan Fan; Fang Wan
Journal:  Cancer Cell Int       Date:  2020-05-07       Impact factor: 5.722

6.  In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination.

Authors:  Giorgia Mandili; Claudia Curcio; Sara Bulfamante; Laura Follia; Giulio Ferrero; Emanuela Mazza; Moitza Principe; Francesca Cordero; Maria Antonietta Satolli; Rosella Spadi; Andrea Evangelista; Daniele Giordano; Duy Viet; Paola Cappello; Francesco Novelli
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.